{
    "nctId": "NCT06503783",
    "briefTitle": "A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors",
    "officialTitle": "A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Solid Tumor",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Phase Ia: Dose limiting toxicity (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Sign the informed consent form voluntarily and follow the protocol requirements;\n2. Gender is not limited;\n3. Age: \u226518 years old and \u226475 years old (stage Ia); \u226518 years old (stage Ib);\n4. Expected survival time \u22653 months;\n5. Patients with locally advanced or metastatic HER2-positive/negative breast cancer and other solid tumors;\n6. Agree to provide archival tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 3 years;\n7. Must have at least one extracranial measurable lesion that meets the RECIST v1.1 definition;\n8. ECOG 0 or 1;\n9. The toxicity of previous antineoplastic therapy has returned to \u2264 grade 1 as defined by NCI-CTCAE v5.0;\n10. No severe cardiac dysfunction, left ventricular ejection fraction \u226550%;\n11. No blood transfusion is allowed within 14 days before the first use of the study drug, and no cell growth factor is allowed. The organ function level must meet the requirements;\n12. Coagulation function: international normalized ratio (INR) \u22641.5, and activated partial thromboplastin time (APTT) \u22641.5ULN;\n13. For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.\n\nExclusion Criteria:\n\n1. Chemotherapy, biological therapy and other anti-tumor therapies have been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil;\n2. History of severe heart disease;\n3. Prolonged QT interval, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;\n4. Active autoimmune and inflammatory diseases;\n5. Other malignancies diagnosed within 5 years before the first dose;\n6. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded;\n7. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure \\&gt; 150 mmHg or diastolic blood pressure \\&gt; 100 mmHg);\n8. A history of ILD requiring steroid therapy, or current ILD or radiation pneumonitis of grade \u22651 according to the RTOG/EORTC definition, or a suspicion of such disease;\n9. Patients with poor glycemic control;\n10. Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;\n11. Patients with primary central nervous system tumors or CNS metastases after failure of local treatment;\n12. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any of BL-M17D1's excipients;\n13. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;\n14. Prior anthracycline therapy with more than the protocol-specified cumulative dose of an anthracycline;\n15. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or active hepatitis C virus infection;\n16. Active infection requiring systemic therapy with a serious infection within 4 weeks prior to informed consent; There were indications of pulmonary infection or active pulmonary inflammation within 2 weeks before informed consent;\n17. Patients with massive or symptomatic effusions, or poorly controlled effusions;\n18. Had participated in another clinical trial within 4 weeks before the first dose;\n19. Pregnant or lactating women;\n20. Patients with superior vena cava syndrome should not be rehydrated;\n21. A history of severe neurological or psychiatric illness;\n22. Severe unhealed wounds, ulcers, or fractures within 4 weeks before signing the informed consent;\n23. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;\n24. History of intestinal obstruction, inflammatory bowel disease or extensive bowel resection or presence of Crohn's disease, ulcerative colitis or chronic diarrhea;\n25. Who are scheduled to receive live vaccine or who receive the vaccine within 28 days before the first dose;\n26. The investigators did not consider it appropriate to apply other conditions for participation in the trial.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}